FDA-APPROVED

Pentosan Polysulfate (PPS)

Sold as Elmiron. FDA-approved for interstitial cystitis. Studied off-label for osteoarthritis and joint pain. Carries a meaningful long-term safety concern (maculopathy) that's worth knowing about up front.

The 30-second read

Pentosan Polysulfate Sodium (PPS) is a semi-synthetic polysaccharide, technically not a peptide, included here because it shows up in the same conversations. It's FDA-approved as Elmiron for interstitial cystitis (a chronic bladder pain condition) and has been used since 1996. It's also been studied for osteoarthritis and joint pain, both as oral therapy and as an injectable formulation more common in veterinary medicine. The most important thing to know: long-term Elmiron use has been associated with a specific eye condition called pigmentary maculopathy that can permanently affect vision. The FDA updated the Elmiron label in 2020 to reflect this risk. PPS is a real drug with real benefits and real risks, not a casual peptide.

Why this is on people's radar

PPS comes up in two distinct contexts. The first is medical: as Elmiron, the only FDA-approved oral medication for interstitial cystitis (IC), a chronic and often debilitating bladder-pain condition. People with IC who haven't responded to other approaches sometimes spend years on Elmiron. The drug works by restoring the protective glycosaminoglycan (GAG) layer of the bladder lining, which is thought to be deficient in IC patients.

The second context is the joint-pain conversation. PPS has anti-inflammatory and chondroprotective (cartilage-supporting) properties that have been studied for osteoarthritis and other joint conditions. In Australia and some other countries, an injectable formulation of pentosan (Pentosan Sodium / Cartrophen Vet) has been used in veterinary medicine for arthritis in dogs and horses for decades. Off-label human use in joint conditions, typically as the oral Elmiron formulation, sometimes as compounded injectable, has emerged in chronic pain and orthopedic communities as an alternative to NSAIDs and steroids.

Then there's the maculopathy story. Starting around 2018, ophthalmologists began reporting cases of a specific pigmentary maculopathy, a degenerative condition affecting the central retina, in patients on long-term high-dose Elmiron. The FDA updated the Elmiron label in 2020 to include this risk. Class-action lawsuits followed. The condition is often called PPS maculopathy and is dose-and-duration related; patients on Elmiron for years at full dose are at meaningfully elevated risk. This isn't a theoretical concern, it's a known long-term adverse effect that anyone considering long-term PPS should know about.

What people are usually trying to do with it

People exploring PPS are usually focused on:

Managing chronic interstitial cystitis (the FDA-approved use)
Reducing joint pain from osteoarthritis (off-label)
Supporting cartilage health and slowing OA progression
An alternative to chronic NSAID use for joint pain
An option after PRP, hyaluronic acid, or other joint interventions haven't worked

What the science actually shows

Plain-English summary:

Interstitial cystitis (FDA-approved indication)

Multiple clinical trials have established Elmiron's modest benefit in IC. The effect size in trials has been characterized as modest, improvement in pain and urinary symptoms in roughly 30 to 40% of patients over 3 to 6 months versus placebo response rates around 15 to 20%.1

Osteoarthritis (off-label)

Multiple human and veterinary trials have studied PPS in osteoarthritis. Results have been mixed but generally favorable, reductions in joint pain, improved function, and signs of cartilage protection in some studies. The injectable formulation (used in veterinary medicine) tends to show stronger effects than oral.2

Mechanism. GAG layer support and anti-inflammatory effects

PPS supports glycosaminoglycan (GAG) production in tissues, has direct anti-inflammatory effects, and has weak heparin-like anticoagulant activity. The mechanisms are well-characterized.3

Pigmentary maculopathy, a real long-term risk

Multiple ophthalmology series since 2018 have reported a specific pattern of pigmentary maculopathy in patients on long-term Elmiron. The FDA updated the label in 2020 to include this risk. Risk increases with cumulative dose and duration of use.4

What hasn't been demonstrated

Whether the benefits outweigh the maculopathy risk for indications other than severe interstitial cystitis. That off-label use for joint pain warrants the maculopathy risk profile. A safe long-term dose that avoids the maculopathy effect.

The honest read

What's solid:

For interstitial cystitis, PPS is a real FDA-approved medication with decades of clinical use. The mechanism is well-characterized. The osteoarthritis evidence, particularly from veterinary use of the injectable formulation, is supportive. For people with IC who have responded to it, the medication is meaningful.

What's a real concern:

The pigmentary maculopathy risk is not theoretical. It's been observed in a meaningful number of patients on long-term Elmiron, the FDA has updated the label, and the condition can be permanent. Anyone considering PPS for any indication needs to weigh that risk against the expected benefit.

What's hyped beyond the evidence:

Treating PPS as a casual joint-pain supplement. The off-label use for osteoarthritis carries the same maculopathy risk as the on-label IC use. For most people with mild-to-moderate joint pain, FDA-approved options (NSAIDs, physical therapy, injection therapies, in some cases newer biologics) have better-characterized benefit/risk profiles. PPS is reasonable to consider when those have failed and the IC use case applies, less reasonable as a first-line approach for joint pain.

Things to know if you're looking into it

FDA-approved as Elmiron: for interstitial cystitis (a chronic bladder-pain condition), approved 1996. The standard dose is 100 mg three times daily. Treatment is typically continuous.
Joint use is off-label: oral Elmiron use for osteoarthritis is off-label in the U.S. The injectable veterinary formulation (Cartrophen) is approved for animals; human injectable use in the U.S. is via compounded preparations and is less regulated.
The maculopathy risk is significant: long-term use (years, cumulative high dose) is associated with a specific pigmentary maculopathy. People on long-term PPS need regular ophthalmology monitoring (typically annual). Visual symptoms, difficulty reading, dimming of central vision, visual distortions, should prompt immediate evaluation.
Other side effects: mild GI symptoms, hair loss, increased bruising/bleeding (heparin-like effects), liver enzyme elevation. Most people tolerate the medication well otherwise.
Healthcare provider involvement: essential. PPS is a real prescription drug with real risks. Self-administering compounded versions outside clinical supervision is genuinely a worse decision than taking most peptides on this site, given the maculopathy concern.
For joint pain: work through the FDA-approved options first (NSAIDs, physical therapy, injection therapies, newer biologics where indicated) before considering off-label PPS, and if you do consider it, do so under clinician supervision with eye monitoring.
Specific dosing protocols, mechanism, and references: all in the "Want to go deeper?" section below.

What people often ask

Is Pentosan Polysulfate a peptide?

Technically no, it's a semi-synthetic sulfated polysaccharide derived from beech-tree xylan. We include it on this site because it shows up in the same conversations as peptides used for joint pain and tissue support, and people deserve a clear explainer either way.

Does it actually help interstitial cystitis?

For some patients, yes, the FDA-approved indication is supported by clinical trials. The effect size is modest, and roughly 30 to 40% of patients respond meaningfully versus 15 to 20% on placebo. It can take 3 to 6 months to assess whether it's helping.

What's the maculopathy concern?

Long-term Elmiron use has been associated with a specific pigmentary maculopathy, degenerative changes in the central retina that can affect vision. Risk increases with cumulative dose and duration. The FDA added this to the Elmiron label in 2020. Anyone on long-term PPS should have regular ophthalmology monitoring.

Should I use it for arthritis?

Off-label, some people do. Whether it's the right approach depends on whether you've worked through FDA-approved options first, whether you're prepared for ophthalmology monitoring, and whether the joint-pain severity warrants the maculopathy risk profile. This is a clinician conversation, not a self-administer one.

Is the injectable form different?

Different administration route, same molecule. The injectable formulation is more common in veterinary medicine (Cartrophen for dogs and horses) and tends to show stronger joint-specific effects. Human injectable use in the U.S. is via compounded preparations and is less regulated than oral Elmiron.

What about hair loss?

Some PPS users report hair thinning. This is listed as an uncommon side effect and is generally reversible with discontinuation.

Can I stop suddenly?

No specific withdrawal pattern has been reported. If you stop, the drug's effects on bladder symptoms or joint pain typically gradually return. Always discuss discontinuation with your prescriber, particularly if you're on it for IC.

FDA and regulatory status

Status as of May 5, 2026: FDA-approved as Elmiron (1996) for the relief of bladder pain or discomfort associated with interstitial cystitis. Approved dose 100 mg three times daily, taken on an empty stomach with water. The FDA updated the Elmiron label in 2020 to include risk of pigmentary maculopathy with long-term use. Off-label use for osteoarthritis and other joint conditions is at the discretion of the prescriber. Status updates land here when they happen.

Want to go deeper? Mechanism, dosing, the maculopathy detail, side-effect profile, and references. Click to expand.

Background

Pentosan Polysulfate Sodium (PPS) is a semi-synthetic sulfated polysaccharide derived from beech tree xylan. Marketed as Elmiron (Janssen, originally), it received FDA approval in 1996 for relief of bladder pain or discomfort associated with interstitial cystitis. The approval was based on clinical trials showing modest improvements in IC symptoms. PPS has heparin-like properties (weak anticoagulant activity) and supports glycosaminoglycan production in tissues.

Mechanism of action

GAG layer support

PPS is thought to restore or supplement the protective glycosaminoglycan (GAG) layer of the bladder mucosa, which is hypothesized to be deficient in IC patients. The GAG layer prevents irritants in urine from reaching underlying nerves and tissues. Similar GAG-supportive effects in joint cartilage form the basis for the osteoarthritis use case.

Anti-inflammatory effects

PPS has direct anti-inflammatory effects in tissue, including reducing inflammatory cytokine production and inhibiting enzymes involved in cartilage breakdown.

Heparin-like anticoagulant activity

PPS has weak anticoagulant properties (about 1/15th the activity of heparin), which can manifest as increased bruising or bleeding tendency and is the basis for the bleeding-related cautions.

FDA-approved dosing (Elmiron)

This is a prescription medication. Dosing is established by your prescriber.

Standard FDA-approved dose: 100 mg orally three times daily, taken on an empty stomach (1 hour before or 2 hours after meals) with water.

Treatment duration: typically continuous. Effect is assessed at 3 to 6 months. Patients who haven't responded by 6 months are usually transitioned off.

Off-label joint protocols: oral dosing similar to IC dose has been used. Compounded injectable PPS (less common in human use) is typically given as a series of injections at intervals.

Long-term monitoring: annual or more frequent ophthalmology examinations are recommended for any patient on Elmiron longer than 1 to 2 years, given the maculopathy risk.

The pigmentary maculopathy concern

Starting around 2018, ophthalmology groups began publishing case series describing a specific pattern of pigmentary maculopathy in patients on long-term high-dose Elmiron. The condition involves degenerative changes in the central retina (macula) that can affect central vision. Symptoms include difficulty reading, dimmed central vision, and metamorphopsia (visual distortion).

Key facts:

Risk is dose-and-duration dependent, patients on high cumulative doses over years are at meaningfully elevated risk
The FDA added this risk to the Elmiron label in 2020
Class-action lawsuits have followed
The condition can be permanent even after discontinuation
Annual ophthalmology examinations are now recommended for any long-term Elmiron user
Visual symptoms warrant immediate evaluation

Side effects and safety profile

Reported across the clinical-trial program and post-marketing surveillance:

Mild GI symptoms (nausea, diarrhea), common
Hair loss, uncommon, usually reversible
Headache, uncommon
Increased bruising or bleeding (from anticoagulant-like activity), uncommon
Liver enzyme elevation, uncommon
Pigmentary maculopathy, long-term, dose-and-duration dependent (see section above)

Caution in patients on anticoagulants or with bleeding disorders. Caution in patients with active bleeding or recent surgery.

References

Mulholland SG, Hanno P, Parsons CL, et al. (1990). "Pentosan polysulfate sodium for therapy of interstitial cystitis. A double-blind placebo-controlled clinical study." Urology, 35(6), 552–558. PubMed
Kumagai K, Shirabe S, Miyata N, et al. (2010). "Sodium pentosan polysulfate resulted in cartilage improvement in knee osteoarthritis: an open clinical trial." BMC Clin Pharmacol, 10, 7. PubMed
Ghosh P, Edelman J, March L, Smith M. (2005). "Effects of pentosan polysulfate in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled pilot study." Curr Ther Res Clin Exp, 66(6), 552–571. PubMed
Pearce WA, Chen R, Jain N. (2018). "Pigmentary maculopathy associated with chronic exposure to pentosan polysulfate sodium." Ophthalmology, 125(11), 1793–1802. PubMed
Hanif AM, Armenti ST, Taylor SC, et al. (2019). "Phenotypic spectrum of pentosan polysulfate sodium-associated maculopathy." JAMA Ophthalmol, 137(11), 1275–1282. PubMed
U.S. Food and Drug Administration. "Elmiron (pentosan polysulfate sodium), prescribing information including 2020 label update for pigmentary maculopathy." FDA.gov

For educational and research purposes only. This is not medical advice. Pentosan Polysulfate Sodium (Elmiron) is FDA-approved for interstitial cystitis. The drug carries a known long-term risk of pigmentary maculopathy that may permanently affect vision. Anyone on long-term PPS should have regular ophthalmology monitoring. Off-label use for joint conditions is at the discretion of a licensed prescriber and should be considered alongside the maculopathy risk profile. Consult a licensed healthcare provider before considering any peptide. PeptideLibraryHub is independent and does not sell peptides or accept money from anyone who does.